PepGen initial DM1 data ‘a clear win,’ says Stifel

After PepGen (PEPG) announced initial clinical data from the five and ten mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1, Stifel says the data demonstrated “a highly promising signal on splicing.” These biomarker results, along with “fairly clean safety,” should increase the probability-of-success for EDODM1 and while there “are a few caveats,” the firm would “call this a clear win in the backdrop of low expectations, especially with the stock trading below cash,” says the analyst, who keeps a Buy rating on PepGen shares.